You are here » Home » Companies » Company Overview » Bombay Oxygen Investments Ltd

Bombay Oxygen Investments Ltd.

BSE: 509470 Sector: Financials
NSE: N.A. ISIN Code: INE01TL01014
BSE 00:00 | 24 Feb 10629.65 173.90
(1.66%)
OPEN

10550.50

HIGH

10691.00

LOW

10299.00

NSE 05:30 | 01 Jan Bombay Oxygen Investments Ltd
OPEN 10550.50
PREVIOUS CLOSE 10455.75
VOLUME 45
52-Week high 14099.95
52-Week low 8511.60
P/E 6.77
Mkt Cap.(Rs cr) 159
Buy Price 10226.00
Buy Qty 1.00
Sell Price 10660.00
Sell Qty 5.00
OPEN 10550.50
CLOSE 10455.75
VOLUME 45
52-Week high 14099.95
52-Week low 8511.60
P/E 6.77
Mkt Cap.(Rs cr) 159
Buy Price 10226.00
Buy Qty 1.00
Sell Price 10660.00
Sell Qty 5.00

Bombay Oxygen Investments Ltd. (BOMBAYOXYGEN) - Company History

Bombay Oxygen Corporation (BOCL) was incorporated in 1960 to manufacture and market industrial gases. Shyam M Ruia is the chairman of the company. The company's manufacturing facilities are located in Nagpur Tarapur Pune Nira Khopoli Kalwe and Mulund all in Maharashtra. BOCL has a collaboration with General Electrodes and Equipments Germany. The company has also entered into an agreement for procuring engineering services from Messer AGS Gmbh. In Mar.'95 it installed a capacity of 2.37 lac cu mtr for the manufacture of oxygen. The company manufactures various industrial gases such as oxygen nitrogen argon compressed air acetylene and medicinal oxygen. Its subsidiaries -- Savita Pharmaceuticals and Raptakos Brett & Company -- are engaged in the manufacture and distribution of pharmaceuticals. The company has designed and developed an indigenous cryogenic liquid oxygen pump for high-pressure gas-filling purposes. In 1996 the company has dis-invested in the shares of Raptakos Brett & Co. Therefore Raptakos Brett & Co as also its subsidiaries Raptakos Brett Test Laboratries and Sattva Pharmaceuticals ceased to be the company's subsidiaries.The company is also implementing new large tonnage Oxygen plant of 130 TPD at Kalwe the same is expected to go on stream in 1999.

.